<DOC>
	<DOCNO>NCT02646475</DOCNO>
	<brief_summary>The overall purpose study learn metabolic effect angiotensin- ( 1-7 ) insulin resistant state associate obesity . Pharmacologic approach increase angiotensin- ( 1-7 ) level action currently development treatment metabolic-related disease obesity type II diabetes , base finding animal study . It unclear peptide contributes regulation metabolism human . The investigator test angiotensin- ( 1-7 ) infusion improve insulin sensitivity measure hyperinsulinemic-euglycemic clamp method individual obesity insulin resistance . The investigator also examine change blood pressure relate hemodynamic hormonal change follow angiotensin- ( 1-7 ) infusion .</brief_summary>
	<brief_title>Metabolic Effects Angiotensin- ( 1-7 )</brief_title>
	<detailed_description>This outpatient study require screen visit two study day Vanderbilt Clinical Research Center . Subjects ask stop taking medication high blood pressure least 2 week prior study . Subjects receive intravenous angiotensin- ( 1-7 ) saline infusion two separate study day , study day last approximately four hour . There least one week washout study day . On study day , subject instrument two intravenous catheter ( one blood sample one drug infusion ) , arm finger blood pressure cuff , sticky patch measure heart rate throughout study . The investigator take baseline measurement blood pressure heart rate collect blood sample . The investigator also perform rebreathing test measure heart 's pumping capacity . After baseline measurement , investigator infuse angiotensin- ( 1-7 ) saline 30 minute , blood pressure heart rate measure every 10 minute . At end 30 minute , blood sample collect rebreathing test repeat . The investigator continue angiotensin- ( 1-7 ) saline infusion additional 2 hour perform hyperinsulinemic-euglycemic clamp measure insulin sensitivity .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Angiotensin I ( 1-7 )</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<criteria>Males female race 18 60 year age Obesity define body mass index 3040 kg/m2 Insulin resistance define homeostasis model assessment 2 insulin resistance ( HOMA2IR ) score &gt; 2.2 Hypertension define two properly measure seat blood pressure reading &gt; 130/85 mmHg , use antihypertensive medication . This blood pressure cutoff allow u include subject prehypertension . Able willing provide inform consent Pregnancy breastfeed Current smoker history heavy smoking ( &gt; 2 packs/day ) History alcohol drug abuse Morbid obesity ( BMI &gt; 40 kg/m2 ) Previous allergic reaction study medication Evidence type I type II diabetes ( i.e . fast glucose &gt; 126 mg/dl , use antidiabetic medication ) Cardiovascular disease hypertension myocardial infarction within 6 month prior enrollment , presence angina pectoris , significant arrhythmia , congestive heart failure ( LV hypertrophy acceptable ) , deep vein thrombosis , pulmonary embolism , second third degree heart block , mitral valve stenosis , aortic stenosis , hypertrophic cardiomyopathy History serious cerebrovascular disease cerebral hemorrhage , stroke , transient ischemic attack History presence immunological hematological disorder Impaired hepatic function [ aspartate amino transaminase ( AST ) and/or alanine amino transaminase ( ALT ) &gt; 2.0 x upper limit normal range ] Impaired renal function ( serum creatinine &gt; 1.5 mg/dl ) Anemia ( hemoglobin &lt; 13.5 g/dl male &lt; 12.5 g/dl female ) Treatment serotoninnorepinephrine reuptake inhibitor ( SNRIs ) norepinephrine transporter ( NET ) inhibitor Treatment phosphodiesterase 5 inhibitor Treatment anticoagulant Treatment chronic systemic glucocorticoid therapy ( 7 consecutive day 1 month ) Treatment investigational drug 1 month precede study Inability give , withdraw , informed consent Other factor investigator 's opinion would prevent subject complete protocol ( i.e. , clinically significant abnormality clinical , mental examination laboratory test inability comply protocol )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>renin-angiotensin system</keyword>
	<keyword>angiotensin</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>blood pressure</keyword>
</DOC>